S
Simone Cazzaniga
Researcher at Centro Studi GISED
Publications - 147
Citations - 2871
Simone Cazzaniga is an academic researcher from Centro Studi GISED. The author has contributed to research in topics: Population & Psoriasis. The author has an hindex of 25, co-authored 129 publications receiving 2122 citations. Previous affiliations of Simone Cazzaniga include University of Milan & University of Bern.
Papers
More filters
Journal ArticleDOI
Prevalence of contact allergy in the general population in different European regions.
Thomas L. Diepgen,Robert Ofenloch,Magnus Bruze,Paola Bertuccio,Simone Cazzaniga,P.-J. Coenraads,Peter Elsner,Margarida Gonçalo,Åke Svensson,Luigi Naldi +9 more
TL;DR: Population‐based studies about contact allergy are scarce and need to be supplemented with more data on animal studies to be certain that contact allergy can be diagnosed and treated.
Journal ArticleDOI
Family history, body mass index, selected dietary factors, menstrual history, and risk of moderate to severe acne in adolescents and young adults
Anna Di Landro,Simone Cazzaniga,Fabio Parazzini,Vito Ingordo,Francesco Cusano,Laura Atzori,Francesco Tripodi Cutrì,Maria Letizia Musumeci,Cornelia Zinetti,Enrico Pezzarossa,Vincenzo Bettoli,Marzia Caproni,Giovanni Lo Scocco,A. Bonci,Pierluca Bencini,Luigi Naldi +15 more
TL;DR: Family history, body mass index, and diet may influence the risk of moderate to severe acne and the influence of environmental and dietetic factors in acne should be further explored.
Journal ArticleDOI
Diet and physical exercise in psoriasis: a randomized controlled trial
Luciana Naldi,Andrea Conti,Simone Cazzaniga,Annalisa Patrizi,Massimiliano Pazzaglia,Anna Lanzoni,Leonardo Veneziano,Giovanni Pellacani +7 more
TL;DR: Increased body mass index and weight gain are risk factors for Psoriasis, and the prevalence of obesity in patients with psoriasis is higher than in the general population.
Journal ArticleDOI
Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland
M. Benzaquen,Luca Borradori,Philippe Berbis,Simone Cazzaniga,Simone Cazzaniga,René Valéro,Marie-Aleth Richard,Laurence Feldmeyer +7 more
TL;DR: DPP4is, especially vildagliptin, are associated with an increased risk for development of BP, and their use needs to be carefully evaluated, particularly in high‐risk patients, such as males and those age 80 years or older.
Journal ArticleDOI
The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience.
Paolo Gisondi,Paola Facheris,Paolo Dapavo,Stefano Piaserico,Andrea Conti,Luigi Naldi,Simone Cazzaniga,Simone Cazzaniga,Piergiorgio Malagoli,Antonio Costanzo +9 more
TL;DR: The "severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2) has spread over the four continents, causing the respiratory manifestations of Coronavirus disease-19 (COVID-19) and satisfying the epidemiological criteria for a pandemic.